-79.9%
FIG vs MRNA
+361.3%
-441.2%
-86.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.8% | +5.4% | -0.6% | +4.6% |
| 7D | -3.8% | -1.1% | -2.7% | -3.8% |
| 30D | -2.3% | +126.1% | -128.4% | -8.7% |
| 3M | +20.0% | +190.0% | -170.1% | +7.6% |
| 6M | -16.7% | +157.2% | -173.9% | -23.8% |
| YTD | -37.9% | +388.2% | -426.1% | -50.6% |
| 1Y | -58.5% | +467.0% | -525.6% | -68.4% |
| All | -79.9% | +361.3% | -441.2% | -85.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling